



GUNDERTON
DETTMER



Tony Huynh

ASSOCIATE

Silicon Valley

P +1 650 463 5352

Tony is a corporate and venture fund associate.

Tony specializes in the formation, organization and operation of venture capital and other private equity funds and their general partner and management company entities in all stages of their operations. Tony's practice also includes the representation of emerging growth companies throughout various stages of their lifecycles, including corporate formation, structuring and governance matters, venture capital financing transactions, and mergers & acquisitions, and the representation of venture capital and private equity funds in connection with their investments.

Credentials

EDUCATION

- University of California, Berkeley, School of Law, J.D.
- University of California, Los Angeles, B.A., Political Science, Sociology

BAR ADMISSIONS

- California

ACHIEVEMENTS

- “Technology and Communications Editor” for the *California Law Review*

Focus Areas

Fund Formation

Fund Operations and Compliance

Fund Investments in Companies

Related News & Insights

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

EVENTS

Webinar: Emerging Fund Managers: You Don't Have a CFO, but You Need to Manage the Cash

CLIENT NEWS

Gunderson Dettmer Represents Addition and a16z in Base Power \$200M Series B Financing

INSIGHTS

Recent Fund Formations Represented by Gunderson Dettmer*

CLIENT NEWS

CLIENT NEWS

SignalFire Secures \$1B in New Funding

CLIENT NEWS

Dragonfly Capital Leads \$16M Financing of Codex

FIRM NEWS

Gunderson Dettmer Wins China Business Law Journal's 2024 "Deals of the Year"

CLIENT NEWS

Prosus Ventures Participates in \$54M Series B Funding of SpotDraft

CLIENT NEWS

Coatue Leads \$250M Series E of Enterprise Browser Island

INSIGHTS

Client Insight: Status of the Corporate Transparency Act as of March 25, 2025

CLIENT NEWS

Gunderson Dettmer Represents The Column Group in Surrozen's \$175 Million Oversubscribed Private Placement

CLIENT NEWS

BioReNuva Announces Strategic Investment From Hallstar